The US Food and Drug Administration issued national priority vouchers to companies studying psilocybin and methylone for the treatment of some mental health disorders. The vouchers were granted under a pilot program launched last year as a way to fast-track the review process for certain drugs seeking approval, potentially speeding up the time it takes for them to reach patients.
Original source: edition.cnn.com